Humanigen Announces Pricing of Public Offering of Five Million Shares …
페이지 정보
작성자 댓글 0건 조회 20회 작성일 21-04-01 10:40본문
Humanigen, Inc. (Nasdaq:HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine storm” with its lead drug candidate lenzilumab™, today announced that it has priced its underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $18.50 per share, resulting in gross proceeds to Humanigen of approximately $92.5 million, before deducting underwriting discounts and com...
관련링크
댓글목록
등록된 댓글이 없습니다.